No Data
Shenzhen Kangtai Biological Products (300601.SZ): Some fundraising projects have been completed, and the surplus funds will be permanently used to supplement working capital.
On December 31, Gelonghui reported that Shenzhen Kangtai Biological Products (300601.SZ) announced it will hold the 25th meeting of the 7th Board of Directors and the 19th meeting of the 7th Supervisory Board on December 31, 2024. The meetings approved the proposal to conclude the projects of issuing convertible corporate bonds to unspecified objects and to permanently supplement the remaining raised funds for working capital. In light of the completion of the projects funded by the raised capital from issuing convertible corporate bonds to unspecified objects, namely the 'Baiwangxin Emergency Engineering & Construction Project' and the 'Adenovirus Vaccine Workshop Project'.
Express News | Kangtai has signed an agency and technology transfer agreement for the 13-valent pneumonia vaccine with a pharmaceutical company in Bangladesh.
Express News | Shenzhen Kangtai Biological Products: Termination of the 2023 Stock Options and Restricted Stock Incentive Plan.
Express News | Shenzhen Kangtai Biological Products: The 20-valent pneumococcal polysaccharide conjugate vaccine has initiated phase I clinical trials.
Express News | Shenzhen Kangtai Biological Products: The combined attenuated live vaccine for measles and rubella has started Phase I clinical trials.
Express News | Shenzhen Kangtai Biological Products: The clinical trial application for bivalent inactivated enterovirus vaccine has been accepted.
No Data
